Omniox
Omniox is a San Francisco-based, venture-backed biopharmaceutical company developing an engineered oxygen-carrier platform intended to selectively oxygenate hypoxic tissues in cancer, cardiovascular disease, and trauma. The company is pre-commercial with no products on market and only 1-10 employees.
- Company typePrivate
- Founded2016
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Omniox does
Omniox is an early-stage, venture-backed biopharmaceutical company headquartered in San Francisco, California (incorporated in Delaware) that is developing an engineered oxygen-carrier platform designed to deliver oxygen specifically to hypoxic tissues. The company's stated therapeutic thesis targets unmet medical needs in cancer, cardiovascular disease, and trauma, where tissue hypoxia contributes to treatment resistance and poor clinical outcomes; the platform is positioned to selectively oxygenate hypoxic tumors and ischemic cardiovascular tissue rather than functioning as a general blood substitute. Technology disclosure is limited to a high-level description of the oxygen-delivery architecture, with no named product candidates, no disclosed patents, no clinical trial data, and no regulatory milestones provided in available sources.
Omniox operates as a private, R&D-only organization with 1-10 employees, no commercial revenue, and no pricing or distribution model yet established. Its business model to date has been capital-formation-driven: cumulative disclosed equity and debt raises total roughly $28-31 million across rounds dated 2013, 2014 (from Casdin Capital and Wellcome Trust, among others), 2016 (~$28M SEC Form D), 2018, 2023, and 2024 (~$3.36M SEC Form D), with named institutional backers including Casdin Capital, Wellcome Trust, Samsara BioCapital, Acadia Woods Partners, Baker Brothers Advisors, EcoR1 Capital, Wavemaker 360, and Plug and Play. The intended end-customers are healthcare providers and patients in oncology and cardiovascular indications, but the company remains pre-commercial with no active distribution or marketing channels.
Governance is led by CEO Jonathan Winger, with founder Stephen Cary and director Ajit Shah. Operating status remains active per the 2024 SEC filing, but there are no public disclosures of clinical milestones, partnerships, or geographic expansion, leaving the company's near-term trajectory dependent on continued capital formation and undisclosed development progress.
Omniox firmographics
Firmographics- Name
- Omniox
- Legal name
- Omniox, Inc.
- Website
- https://omniox.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Omniox is a San Francisco-based, venture-backed biopharmaceutical company developing an engineered oxygen-carrier platform intended to selectively oxygenate hypoxic tissues in cancer, cardiovascular disease, and trauma. The company is pre-commercial with no products on market and only 1-10 employees.
- Ownership category
- akta.pro rank
Omniox industry classification
Industry- Product category
- Biopharmaceuticals — Oxygen-Delivery Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC) (HLAHAGAD)
Keywords
Where Omniox is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Omniox business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Omniox product offering
Product offeringCore offering
Omniox develops an engineered oxygen carrier platform technology designed to deliver oxygen specifically to hypoxic tissues. The company targets unmet medical needs in cancer, cardiovascular disease, and trauma by oxygenating tissues where conventional oxygen delivery is insufficient, aiming to overcome treatment resistance associated with tumor and tissue hypoxia. The company is pre-commercial and currently focused on technology development rather than marketed products.
Product overview
Omniox is an early-stage biopharmaceutical company developing an oxygen-delivery platform technology. The company's engineered oxygen carrier technology is designed to target unmet medical needs related to hypoxic diseases, specifically aiming to improve treatment outcomes for conditions such as cancer and cardiovascular diseases by specifically oxygenating hypoxic tissues. No distinct named products or modules were identified in the available sources.
Differentiator
Problem solved
Functional benefit
Products and services
- Oxygen-Delivery Platform Technology Engineered oxygen carrier platform designed to selectively deliver oxygen to hypoxic tissues in cancer, cardiovascular disease, and trauma indications, intended for healthcare providers and clinical institutions managing treatment-resistant hypoxic conditions.
Companies that use Omniox
Customer profileSegments1 record
Ideal customer profiles1 record
Omniox technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Omniox partnerships and signals
Strategic signalScale indicators2 records
Recent moves3 records
Expansion highlights4 records
Omniox competitors and assessment
Company assessmentDirect peers
- Diffusion Pharmaceuticals: Developed trans sodium crocetinate (TSC), a small-molecule oxygen diffusion enhancer targeting hypoxic tumors and stroke. Closely comparable in therapeutic strategy — enhancing oxygen delivery to hypoxic tissues — though delivered via small molecule rather than biologic carrier.
- NuvOx Pharma: Clinical-stage biotech developing dodecafluoropentane (DDFPe) emulsion as an oxygen-transport agent for cancer (as a radiosensitizer), stroke, and sickle cell disease. Direct peer targeting the same hypoxia-modulation thesis in oncology and ischemic indications.
- Savara Inc. Acquired the legacy oxygen-therapeutic assets of Mast Therapeutics, which developed polymerized hemoglobin for sickle cell vaso-occlusive crisis. Direct historical peer in the hemoglobin-based oxygen carrier space targeting similar hypoxic indications.
- Prolong Pharmaceuticals: Developed Sanguinate, a PEGylated bovine hemoglobin-based oxygen carrier for sickle cell disease and other hypoxic conditions. Most directly comparable to Omniox as both pursue hemoglobin/oxygen-carrier biologics for tissue hypoxia, though Prolong has been relatively quiet in recent years.
- Hemarina: French biotech developing HEMO2Life, a marine worm (Arenicola marina) hemoglobin-based oxygen carrier for organ preservation and therapeutic oxygen delivery. Direct peer in the oxygen-carrier biologic modality, with applications in ischemia-reperfusion that overlap Omniox's cardiovascular positioning.
Broad incumbents
- Regeneron Pharmaceuticals: Major biologics platform company with significant oncology and cardiovascular franchises. Comparable as a large-scale operator of protein-engineering platforms targeting tissue-level disease mechanisms, and a plausible strategic acquirer profile.
- BioMarin Pharmaceutical: Established biologics-focused rare disease company with deep expertise in manufacturing and commercializing biologic therapeutics. Relevant as a benchmark for capital-efficient biologic platform development and a potential strategic acquirer for hypoxia-modulating platforms.
- Vertex Pharmaceuticals: Large-cap biotech with a platform-based approach to serious diseases (CF, sickle cell, pain). Comparable as a successful example of a biotech scaling a mechanistic platform across multiple indications, and a relevant reference for Omniox's trajectory potential.
Emerging players
- Alpine Immune Sciences: Small-cap immunology platform biotech with protein-engineering expertise targeting inflammatory and oncology indications. Comparable as a similarly-sized, similarly-platform-oriented biotech that advanced to late-stage clinical development and strategic exit.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Omniox social profiles
Digital presenceOmniox financial estimates
Financial estimateRevenue estimate
Valuation estimate
Omniox leadership team
Management profileNumber of profiles
Profiles3 records
Omniox funding detail
Funding detailFunding overview
Funding rounds7 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Omniox M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Omniox
What does Omniox do?
Omniox develops an engineered oxygen carrier platform technology designed to deliver oxygen specifically to hypoxic tissues. The company targets unmet medical needs in cancer, cardiovascular disease, and trauma by oxygenating tissues where conventional oxygen delivery is insufficient, aiming to overcome treatment resistance associated with tumor and tissue hypoxia. The company is pre-commercial and currently focused on technology development rather than marketed products.
Is Omniox a public or private company?
Omniox is a private company. It is classified as venture growth investor backed and is currently operating.
When was Omniox founded?
Omniox was founded in 2016. It employs 1 to 10 people.
Where is Omniox based?
Omniox is headquartered in San Francisco, United States, in the North America region.
Who are Omniox's main competitors?
Direct peers on record are Diffusion Pharmaceuticals, NuvOx Pharma, Savara Inc., Prolong Pharmaceuticals and Hemarina. Broad incumbents are Regeneron Pharmaceuticals, BioMarin Pharmaceutical and Vertex Pharmaceuticals. Alpine Immune Sciences is listed as an emerging player.
Does Omniox have an API?
No public API is recorded for Omniox.
What industry is Omniox in?
Omniox's product category is Biopharmaceuticals — Oxygen-Delivery Therapeutics. Its primary akta.pro industry code is HLAHAGAD, Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC). Its NAICS code is 325414 and its SIC code is 8731.